Alzheimer’s disease has long been one of the most challenging neurological disorders, affecting over 50 million people worldwide, with numbers expected to double by 2050. For decades, treatments mainly focused on easing symptoms, such as helping patients remember a name, a place, or a moment. But what if there was a way to slow, halt, or even prevent the disease itself? That’s where disease-modifying therapies (DMTs) come in.
The global Alzheimer’s disease-modifying therapies (DMTs) market was estimated at $235.8 million in 2024 and is projected to reach $13.1 billion by 2030, growing at a CAGR of 67.8% during the forecast period. This rapid growth highlights the urgent need for therapies that go beyond symptom management, offering real potential to slow or modify the course of the disease.